Compare Oncolys BioPharma, Inc. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -349.00
3
Poor long term growth as Operating profit has grown by an annual rate 1.24% of over the last 5 years
4
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
JPY 70,783 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.78
-46.15%
19.70
Revenue and Profits:
Net Sales:
500 Million
(Quarterly Results - Jun 2026)
Net Profit:
-348 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.36%
0%
-2.36%
6 Months
30.57%
0%
30.57%
1 Year
373.26%
0%
373.26%
2 Years
448.94%
0%
448.94%
3 Years
377.22%
0%
377.22%
4 Years
459.72%
0%
459.72%
5 Years
133.72%
0%
133.72%
Oncolys BioPharma, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-36.50%
EBIT Growth (5y)
1.24%
EBIT to Interest (avg)
-352.14
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.01
Tax Ratio
0.26%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
20.75
EV to EBIT
-43.23
EV to EBITDA
-43.23
EV to Capital Employed
92.71
EV to Sales
2267.57
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-214.48%
ROE (Latest)
-46.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
500.00
3.10
16,029.03%
Operating Profit (PBDIT) excl Other Income
-346.80
-420.70
17.57%
Interest
5.90
3.00
96.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-347.70
-414.50
16.12%
Operating Profit Margin (Excl OI)
-693.80%
-136,155.70%
13,546.19%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 16,029.03% vs 0.00% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 16.12% vs 6.01% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
28.50
31.40
-9.24%
Operating Profit (PBDIT) excl Other Income
-2,023.80
-1,680.60
-20.42%
Interest
5.20
4.60
13.04%
Exceptional Items
-2.80
-17.10
83.63%
Consolidate Net Profit
-2,058.00
-1,684.80
-22.15%
Operating Profit Margin (Excl OI)
-70,905.50%
-53,575.20%
-1,733.03%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -9.24% vs -50.16% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -22.15% vs 13.09% in Dec 2024
About Oncolys BioPharma, Inc. 
Oncolys BioPharma, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






